Pfizer, Inc. | Pfizer | Maryland | state | 2009 | $56,291 | | tax credit/rebate |
Novartis Pharmaceuticals Corporation | Novartis | Maryland | state | 2008 | $56,054 | | tax credit/rebate |
Shire Holdings US, AG | Takeda Pharmaceutical | Maryland | state | 2005 | $53,032 | | tax credit/rebate |
Amgen, Inc. | Amgen | Maryland | state | 2012 | $50,617 | | tax credit/rebate |
Teva Biopharmaceuticals, Inc. | Teva Pharmaceutical Industries | Maryland | state | 2012 | $50,570 | | tax credit/rebate |
Sucampo Pharmaceuticals, Inc. | Mallinckrodt | Maryland | state | 2004 | $50,128 | | tax credit/rebate |
Otsuka America, Inc. | Otsuka Pharmaceutical | Maryland | state | 2004 | $47,393 | | tax credit/rebate |
United Therapeutics Corporation & Subs. | United Therapeutics | Maryland | state | 2012 | $42,268 | | tax credit/rebate |
TEVA Biopharmaceuticals, Inc. | Teva Pharmaceutical Industries | Maryland | state | 2009 | $41,319 | | tax credit/rebate |
Novartis Pharmaceuticals Corporation | Novartis | Maryland | state | 2009 | $39,846 | | tax credit/rebate |
Eli Lilly and Company | Eli Lilly | Maryland | state | 2012 | $39,722 | | tax credit/rebate |
Novartis Pharmaceuticals Corporation | Novartis | Maryland | state | 2005 | $38,780 | | tax credit/rebate |
Amgen, Inc. | Amgen | Maryland | state | 2009 | $38,772 | | tax credit/rebate |
Novartis Pharmaceuticals Corporation | Novartis | Maryland | state | 2007 | $37,440 | | tax credit/rebate |
Medimmune Oncology, Inc. | AstraZeneca | Maryland | state | 2007 | $36,938 | | tax credit/rebate |
Eli Lilly and Company | Eli Lilly | Maryland | state | 2004 | $34,995 | | tax credit/rebate |
Emergent Product Development Gaithersburg, Inc. | Emergent BioSolutions | Maryland | state | 2005 | $34,357 | | tax credit/rebate |
Macrogenics, Inc. | MacroGenics | Maryland | state | 2005 | $34,280 | | tax credit/rebate |
Pfizer Inc. | Pfizer | Maryland | state | 2004 | $33,734 | | tax credit/rebate |
Shire Holding US AG | Takeda Pharmaceutical | Maryland | state | 2008 | $33,609 | | tax credit/rebate |
Eli Lilly and Company | Eli Lilly | Maryland | state | 2007 | $32,430 | | tax credit/rebate |
Sucampo Pharmaceuticals, Inc. | Mallinckrodt | Maryland | state | 2007 | $31,263 | | tax credit/rebate |
Emergent Product Development Gaithersburg, Inc. | Emergent BioSolutions | Maryland | state | 2008 | $31,261 | | tax credit/rebate |
Shire US Manufacturing, Inc. | Takeda Pharmaceutical | Maryland | state | 2009 | $30,126 | | tax credit/rebate |
Novartis Pharmaceuticals Corporation | Novartis | Maryland | state | 2004 | $29,577 | | tax credit/rebate |
Shire Holdings US AG | Takeda Pharmaceutical | Maryland | state | 2007 | $27,738 | | tax credit/rebate |
Macrogenics, Inc. | MacroGenics | Maryland | state | 2004 | $25,397 | | tax credit/rebate |
Emergent BioSolutions, Inc. & Subsidiaries | Emergent BioSolutions | Maryland | state | 2009 | $25,247 | | tax credit/rebate |
Eli Lilly and Company | Eli Lilly | Maryland | state | 2005 | $19,898 | | tax credit/rebate |
Cambrex Corporation | Cambrex | Maryland | state | 2004 | $19,690 | | tax credit/rebate |
Macrogenics, Inc. | MacroGenics | Maryland | state | 2005 | $19,498 | | tax credit/rebate |
United Therapeutics Corporation | United Therapeutics | Maryland | state | 2005 | $19,409 | | tax credit/rebate |
Sucampo Pharma Americas, Inc. | Mallinckrodt | Maryland | state | 2009 | $17,600 | | tax credit/rebate |
United Therapeutics Corporation & Subs. | United Therapeutics | Maryland | state | 2009 | $16,360 | | tax credit/rebate |
Eisai Inc. | Eisai | Maryland | state | 2009 | $14,019 | | tax credit/rebate |
Pharmacia Corporation | Pfizer | Maryland | state | 2007 | $9,773 | | tax credit/rebate |
Novo Nordisk, Inc. | Novo Holdings A/S | Maryland | state | 2012 | $8,737 | | tax credit/rebate |
EMD Serono, Inc. | Merck KGaA (EMD) | Maryland | state | 2009 | $7,887 | | tax credit/rebate |
United Therapeutics Corporation | United Therapeutics | Maryland | state | 2008 | $7,587 | | tax credit/rebate |
Novartis Pharmaceuticals Corporation | Novartis | Maryland | state | 2012 | $5,264 | | tax credit/rebate |
Pharmacia Corporation | Pfizer | Maryland | state | 2005 | $4,398 | | tax credit/rebate |
United Therapeutics Corporation | United Therapeutics | Maryland | state | 2004 | $3,426 | | tax credit/rebate |
Serono, Inc. | Merck KGaA (EMD) | Maryland | state | 2004 | $2,732 | | tax credit/rebate |
Pharmacia Corporation | Pfizer | Maryland | state | 2004 | $1,884 | | tax credit/rebate |
EMD Serono, Inc. | Merck KGaA (EMD) | Maryland | state | 2012 | $1,480 | | tax credit/rebate |
Astellas Pharma US, Inc. | Astellas Pharma | Maryland | state | 2007 | $1,236 | | tax credit/rebate |
Serono, Inc. | Merck KGaA (EMD) | Maryland | state | 2005 | $1,205 | | tax credit/rebate |
Anda Pharmaceuticals, Inc. | AbbVie | Mississippi | state | 2012 | $500,000 | | grant |
Boehringer Ingelheim Roxane, Inc./Roxane Laboratories, Inc. | Hikma Pharmaceuticals | Ohio | state | 2012 | undisclosed | | enterprise zone |
APTALIS PHARMATECH INC | AbbVie | Ohio | state | 2013 | $25,390 | | training reimbursement |
Roxane Laboratories, Inc. et al. | Hikma Pharmaceuticals | Ohio | state | 1994 | undisclosed | | tax credit/rebate |
Ben Venue Laboratories, Inc. | Boehringer Ingelheim | Ohio | state | 1999 | undisclosed | | tax credit/rebate |
Anda Pharmaceuticals, Inc. | AbbVie | Ohio | state | 2001 | undisclosed | | tax credit/rebate |
Roxane Laboratories, Inc. et al. | Hikma Pharmaceuticals | Ohio | state | 2002 | undisclosed | | tax credit/rebate |
PharmaForce, Inc. | Daiichi Sankyo | Ohio | state | 2004 | undisclosed | | tax credit/rebate |
Abbott Laboratories, Ross Products Division | Abbott Laboratories | Ohio | state | 2006 | undisclosed | | tax credit/rebate |
Genentech Inc | Roche | Oregon | state | 2013 | $3,340,842 | | tax credit/rebate |
Genentech | Roche | Oregon | state | 2013 | $227,332 | | property tax abatement |
Alliance Pharma, Inc. | Alliance Pharma PLC | Pennsylvania | state | 2013 | $100,000 | | tax credit/rebate |
Endo Pharmaceuticals | Endo International | Pennsylvania | state | | $750,000 | | grant |
Alexion Pharmaceuticals | AstraZeneca | Rhode Island | state | 2013 | undisclosed | | tax credit/rebate |
BAUSH & LOMB | Bausch Health | South Carolina | state | 2010 | $615,965 | | training reimbursement |
ST. JUDE MEDICAL | Abbott Laboratories | South Carolina | state | 2009 | $59,305 | | training reimbursement |
ETHICON ENDO-SURGERY INC | Johnson & Johnson | New Mexico | state | 2012 | $281,091 | | tax credit/rebate |
Genzyme Corporation | Sanofi | New Mexico | state | 2008 | $277,372 | | training reimbursement |
ABBOTT MEDICAL OPTICS INC. | Abbott Laboratories | California | state | 2013 | $73,582 | | training reimbursement |
Dr. Reddys Laboratories Louisiana LLC | Dr. Reddy's Laboratories | Louisiana | state | 2013 | $514,750 | | property tax abatement |
Bristol-Myers Squibb | Bristol-Myers Squibb | Massachusetts | state | 2006 | $67,000,000 | | MEGADEAL (Archived) |
Ultragenyx Pharmaceutical, Inc. | Ultragenyx Pharmaceutical | California | state | 2014 | $2,100,000 | | tax credit/rebate |
Novartis Pharmaceuticals Corp. | Novartis | California | state | 2014 | $1,000,000 | | tax credit/rebate |
SANOFI AVENTIS US LLC | Sanofi | Washington | state | 2012 | $70,422 | | tax credit/rebate |
AMRI BOTHELL RESEARCH CENTER INC | Curia Inc. | Washington | state | 2012 | $41,418 | | tax credit/rebate |
EMERGENT PRODUCT DEVELOPMENT SEATTLE LLC | Emergent BioSolutions | Washington | state | 2012 | $47,245 | | tax credit/rebate |
GILEAD SCIENCES INC | Gilead Sciences | Washington | state | 2012 | $108,730 | | tax credit/rebate |
IMMUNE DESIGN CORP | Merck | Washington | state | 2012 | $4,408 | | tax credit/rebate |
NOVO NORDISK INC | Novo Holdings A/S | Washington | state | 2012 | $219,157 | | tax credit/rebate |
SEATTLE GENETICS INC | Seattle Genetics Inc. | Washington | state | 2012 | $19,023 | | tax credit/rebate |
ZYMOGENETICS INC | Bristol-Myers Squibb | Washington | state | 2012 | $19,311 | | tax credit/rebate |
AMRI BOTHELL RESEARCH CENTER INC | Curia Inc. | Washington | state | 2012 | $106,749 | | tax credit/rebate |
EMERGENT PRODUCT DEVELOPMENT SEATTLE LLC | Emergent BioSolutions | Washington | state | 2012 | $101,569 | | tax credit/rebate |
GILEAD SCIENCES INC | Gilead Sciences | Washington | state | 2012 | $11,724 | | tax credit/rebate |
NOVO NORDISK INC | Novo Holdings A/S | Washington | state | 2012 | $53,148 | | tax credit/rebate |
OMEROS CORP | Omeros Corp. | Washington | state | 2012 | $44,191 | | tax credit/rebate |
ONCOTHYREON INC | Seattle Genetics Inc. | Washington | state | 2012 | $19,669 | | tax credit/rebate |
SEATTLE GENETICS INC | Seattle Genetics Inc. | Washington | state | 2012 | $13,467 | | tax credit/rebate |
ZYMOGENETICS INC | Bristol-Myers Squibb | Washington | state | 2012 | $102,839 | | tax credit/rebate |
IDEXX OPERATIONS INC | IDEXX Laboratories | Maine | state | 2014 | $58,245 | | property tax abatement |
IDEXX LAB INC | IDEXX Laboratories | Maine | state | 2014 | $37,045 | | property tax abatement |
ALERE SCARBOROUGH, INC. | Abbott Laboratories | Maine | state | 2014 | $13,652 | | property tax abatement |
IDEXX PHARMACEUTICALS INC | IDEXX Laboratories | Maine | state | 2014 | $3,832 | | property tax abatement |
IDEXX DISTRIBUTION INC | IDEXX Laboratories | Maine | state | 2014 | $1,144 | | property tax abatement |
Blueprint Medicines Corp | Blueprint Medicines | Massachusetts | state | 2013 | $45,000 | | tax credit/rebate |
Moderna Therapeutics, Inc | Moderna Inc. | Massachusetts | state | 2013 | $147,996 | | tax credit/rebate |
Foundation Medicine, Inc. | Roche | Massachusetts | state | 2013 | $150,000 | | tax credit/rebate |
Aegerion Pharmaceuticals, Inc. | Amryt Pharma | Massachusetts | state | 2013 | $160,000 | | tax credit/rebate |
Moderna Therapeutics, Inc | Moderna Inc. | Massachusetts | state | 2013 | $170,504 | | tax credit/rebate |
Blueprint Medicines Corp | Blueprint Medicines | Massachusetts | state | 2013 | $200,000 | | tax credit/rebate |
Foundation Medicine, Inc. | Roche | Massachusetts | state | 2013 | $300,309 | | tax credit/rebate |
Epizyme, Inc. | Epizyme | Massachusetts | state | 2013 | $416,500 | | tax credit/rebate |
Merrimack Pharmaceuticals, Inc | Merrimack Pharmaceuticals | Massachusetts | state | 2013 | $490,000 | | tax credit/rebate |
Shire Human Genetic Therapies, Inc. | Takeda Pharmaceutical | Massachusetts | state | 2013 | $750,000 | | tax credit/rebate |